Billings, MT 的 非小細胞肺癌 臨床試驗
17 項針對 非小細胞肺癌 的研究正在 Billings（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
招募中3 期
- St. Vincent Frontier Cancer Center-Research ( Site 0105), Billings
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
招募中3 期
- Billings Clinic Cancer Center, Billings
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Billings Clinic Cancer Center, Billings
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
招募中3 期
- Billings Clinic ( Site 3255), Billings
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
招募中3 期
- Billings Clinic Cancer Center, Billings
- Saint Vincent Frontier Cancer Center, Billings
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
招募中3 期
- St. Vincent Frontier Cancer Center, Billings
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
招募中3 期
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana, Billings
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
招募中3 期
- SCL Health - Montana, Billings
- SCL Health - Montana, Billings
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
招募中2 期
- Billings Clinic Cancer Center, Billings
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
招募中2 期
- St. Vincent Frontier Cancer Center, Billings
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
招募中1/2 期
- Intermountain Health - St. Vincent Frontier Cancer Center, Billings
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
招募中2 期
- Billings Clinic Cancer Center, Billings
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- Billings Clinic Cancer Center, Billings
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- Billings Clinic Cancer Center, Billings
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- Billings Clinic Cancer Center, Billings
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
招募中觀察性研究
- Billings Clinic Cancer Center, Billings
- Montana Cancer Consortium NCORP, Billings
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Billings
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
Billings 的其他研究
- 前列腺癌15 項研究
- 肺癌13 項研究
- 乳癌10 項研究
- 卵巢癌9 項研究
- 黑色素瘤7 項研究
- 慢性淋巴性白血病7 項研究
- 急性髓系白血病7 項研究
- 膀胱癌6 項研究
- 結腸癌6 項研究
- 大腸直腸癌6 項研究
- 直腸癌5 項研究
- 頭頸部鱗狀細胞癌4 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。